Paper
The development of Wy-41,195, an orally effective antiallergic drug in animal models
Published Jun 1, 1986 · A. Lewis, R. Carlson, T. Forster
Agents and Actions
1
Citations
0
Influential Citations
Abstract
Introduction Disodium cromoglycate (DSCG) administered by aerosol is well established as a prophylactic treatment for asthma. Since it is not effective orally and does not benefit all asthmatics, the search for a more potent and orally effective analog has attracted the attention of numerous pharmaceutical companies [1, 2]. Unfortunately, a poor correlation exists between preclinical screening models and clinical activity [3]. The former are based on the premise that DSCG stabilizes mast cell membranes and prevents the release of allergic mediators induced by antigen-cell bound IgE interaction. This review is an account of the preclinical and clinical development of Wy-41,195 (Fig. 1), an orally effective antiallergic compound. It was originally selected from a series of oxanilic acids [4] that were effective in rat passive cutaneous anaphylaxis (PCA), a screening test adopted for predicting DSCG-like antiallergic activity. However, in addition to its action on the mast cell, DSCG inhibits reflex bronchoconstriction in dogs [5] and bronchoconstriction induced in man by hyperventilation [6], cold air [7] and SO2 [8], events not associated with mast cell activation. Consequently, we have also examined the effects of Wy-41,195 in preclinical models involving reflex bronchoconstriction and airways hyperresponsiveness.
Sign up to use Study Snapshot
Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.
Full text analysis coming soon...